Clinical trials: Renoprotection
Type2 Diabetes
Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES
The current study aims to explore the clinical effects and mechanistics of mono- and combination therapy with SGLT-2 inhibitor empagliflozin and DPP-4 inhibitor linagliptin on renal physiology and biomarkers in metformin-treated…
- Trial name
- RACELINES (NCT03433248)
- Testing
- EMPA/LINA 10/5 mg QD (n=22), LINA/EMPA 5/10 mg QD (N=22), Gliclazide 30 mg QD/BID (N=22)
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- M.H.H. Kramer
Type 2 Diabetes, Microalbuminuria
Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria
Aim: To evaluate the renoprotective effect as reflected by short-term changes in albuminuria of ultra high doses of irbesartan in Type 2 diabetic patients with microalbuminuria Design: A double-masked randomized cross-over trial…
- Trial name
- NCT00320879
- Testing
- irbesartan
- Where
- Denmark
- Volunteers
- 52 people
- Sponsor
- Steno Diabetes Center Copenhagen
Acute Kidney Injury, Cardiac Surgery
proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2
Multi-centre, triple-blinded (patients, physicians, investigators), parallel-group, balanced (1:1), stratified (sex, type 2 diabetes mellitus), randomized, controlled (placebo), phase IV clinical trial to investigate the…
- Conditions
- Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor
- Trial name
- MERCURI-2 (NCT05590143)
- Testing
- Dapagliflozin 10 MG Oral Tablet [Farxiga]
- Where
- 6 sites in Netherlands
- Volunteers
- 784 people
- Sponsor
- Amsterdam UMC
Non-diabetic Nephropathy With Hypertension
ARIA (Atacand Renoprotection In NephropAthy Pt.)
To determine the effective dose of candesartan cilexetil for reduction of urinary protein excretion in hypertensive patients with non-diabetic chronic kidney disease with baseline urinary protein/creatinine ratio between 500mg/g…
- Trial name
- PCR (NCT00573430)
- Testing
- Candesartan Cilexetil, Candesartan Cilexetil 32mg
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- AstraZeneca
Renal Insufficiency,Chronic, Disease Progression
Long-Term Renoprotection of Optimal Antiproteinuric Doses of Benazepril and Losartan in Chronic Renal Insufficiency
The primary goal of the trial was to evaluate whether the optimal antiproteinuric doses of benazepril (an ACE inhibitor) or losartan (an ARB), as compared with their conventional doses, can safely improve the long-term renal…
- Conditions
- Renal Insufficiency,Chronic, Disease Progression, Proteinuria, Dose-Response Relationship,Drug
- Trial name
- NCT00338091
- Testing
- Benazepril, Losartan
- Where
- China
- Sponsor
- Southern Medical University, China
Severe Malaria, Malaria,Falciparum
Effect of Paracetamol on Kidney Function in Severe Malaria
A randomised open labeled, parallel-group, controlled trial to assess the efficacy of paracetamol to reduce kidney dysfunction caused by cell-free haemoglobin-mediated oxidative damage in paediatric patients with falciparum…
- Conditions
- Severe Malaria, Malaria,Falciparum, Acute Kidney Injury, Paracetamol
- Trial name
- PROTECtS (NCT04251351)
- Testing
- Paracetamol, Mechanical antipyresis
- Where
- Democratic Republic of the Congo
- Volunteers
- 460 people
- Sponsor
- University of British Columbia
Type 2 Diabetes
Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes
The aim of this study is to detail the (mechanisms underlying the) actions of the DPP-4 inhibitor linagliptin on the renal system in patients with type 2 diabetes mellitus.
- Trial name
- RENALIS (NCT02106104)
- Testing
- Linagliptin 5 mg QD (N=24), Glimepiride 1 mg QD (N=24)
- Where
- Netherlands
- Volunteers
- 48 people
- Sponsor
- Amsterdam UMC, location VUmc
Type 2 Diabetes Mellitus, Diabetic Kidney Disease
Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.
Current study will render insight in to the role of renal hypoxia in the diabetic kidney and is able to associate its finding with measurements of renal perfusion and glomerular filtration rate.
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Diabetic Nephropathy, Renal Hypoxia
- Trial name
- ROCKIES (NCT04027530)
- Testing
- Ertugliflozin 15 mg
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Chronic Renal Failure
Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial to investigate the renoprotective efficacy of combined pentoxifylline (PTX) and angiotensin receptor blockers (valsartan), compared with placebo…
- Trial name
- CKD (NCT01377285)
- Testing
- ARB, Pentoxifylline
- Where
- Taiwan
- Volunteers
- 350 people
- Sponsor
- National Taiwan University Hospital
Diabetic Nephropathy
Renoprotection in Early Diabetic Nephropathy in Pima Indians
This investigation is a randomized, double-blinded, placebo-controlled clinical trial in adult diabetic Pima Indians with normal urinary albumin excretion (albumin-to-creatinine ration less than 30 mg/g) or microalbuminuria…
- Trial name
- NCT00340678
- Testing
- Losartan
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 2 Diabetes, Diabetic Nephropathy
Pioglitazone and Losartan Provides Additional Renoprotection
Peroxisomal proliferator-activated receptor agonist pioglitazone and rosiglitazone are currently used in the treatment of type 2 diabetes, as efficient insulin sensitizers alone or in combination with insulin.angiotensin II…
- Trial name
- NCT00364988
- Testing
- pioglitazone+losartan, losartan
- Volunteers
- 60 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Diabetic Nephropathy
Spironolactone in Diabetic Nephropathy
The aim of the study was to evaluate the renoprotective effect (i.e. albuminuria- and bloodpressure lowering effect) of spironolactone 25 mg o.d.
- Trial name
- NCT00317954
- Testing
- Spironolactone
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Steno Diabetes Center Copenhagen